EICHORCondition: Non Small Cell Lung Cancer · Sponsor: VA Office of Research and Development
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will be enrolled at multiple Veterans Affairs Medical Centers.
This description comes directly from the study's public registry record.
Daniel S Shin, MD PhD · (713) 578-4126 · Daniel.Shin@va.gov
Quillan Huang, MD · (713) 791-1414 · Quillan.Huang@va.gov
Always discuss trial participation with your own doctor first.
| VA Long Beach Healthcare System, Long Beach, CA | Long Beach, California, United States | Not Yet Recruiting |
| VA Northern California Health Care System, Mather, CA | Sacramento, California, United States | Not Yet Recruiting |
| VA San Diego Healthcare System, San Diego, CA | San Diego, California, United States | Recruiting |
| VA Ann Arbor Healthcare System, Ann Arbor, MI | Ann Arbor, Michigan, United States | Recruiting |
| Michael E. DeBakey VA Medical Center, Houston, TX | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05467748